LifeMD (LFMD) Projected to Post Earnings on Thursday

LifeMD (NASDAQ:LFMD) will likely be announcing its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $62.07 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

LifeMD Trading Down 0.5%

LFMD opened at $6.12 on Thursday. The stock has a market capitalization of $290.21 million, a P/E ratio of -29.14 and a beta of 1.67. LifeMD has a 12 month low of $3.99 and a 12 month high of $15.84. The firm’s fifty day simple moving average is $6.31 and its 200 day simple moving average is $8.76. The company has a current ratio of 0.77, a quick ratio of 0.72 and a debt-to-equity ratio of 9.21.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LFMD shares. Zacks Research raised shares of LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. KeyCorp cut their price objective on shares of LifeMD from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 6th. Lake Street Capital cut their price target on shares of LifeMD from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeMD in a research report on Wednesday, October 8th. Finally, HC Wainwright cut their price target on shares of LifeMD from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.17.

Insider Buying and Selling

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total transaction of $444,000.00. Following the sale, the insider directly owned 605,000 shares of the company’s stock, valued at $3,581,600. The trade was a 11.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 18.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On LifeMD

A number of institutional investors and hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of LifeMD by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock valued at $270,000 after purchasing an additional 2,235 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of LifeMD by 110.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after purchasing an additional 2,452 shares during the period. Rhumbline Advisers raised its holdings in shares of LifeMD by 8.7% in the 2nd quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock valued at $730,000 after purchasing an additional 4,281 shares during the period. Legal & General Group Plc raised its holdings in shares of LifeMD by 187.4% in the 2nd quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock valued at $138,000 after purchasing an additional 6,614 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in shares of LifeMD by 2,180.0% in the 2nd quarter. New York State Common Retirement Fund now owns 11,400 shares of the company’s stock valued at $155,000 after purchasing an additional 10,900 shares during the period. 35.52% of the stock is owned by institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.